Estimativas das pressões pulmonares para o tratamento

https://academic.oup.com/eurheartj/article/44/37/3487/7287528

Three eligible randomized clinical trials were identified that included 1898 outpatients in New York Heart Association functional classes II–IV, either hospitalized for HF in the prior 12 months or with elevated plasma NT-proBNP concentrations. The mean follow-up was 14.7 months, 68% of the patients were men, and 66% had an EF ≤ 40%. Compared with patients in the control group, the HR for total HHF in those randomized to PA pressure monitoring was 0.70 (0.58–0.86) (P = .0005). The corresponding HR for the composite of total HHF, urgent visits, and all-cause mortality was 0.75 and for all-cause mortality 0.92 (Figure 1). Subgroup analyses, including EF phenotype, revealed no evidence of heterogeneity in the treatment effect.

.

This commercially available technology uses a wireless implantable sensor powered externally by radiofrequency energy placed in a branch of the left pulmonary artery to transmit daily snapshot estimates of PAP to health-care providers, thus facilitating close remote patient management without the need for in-person visits, and timely dynamic adjustments of HF treatments as required.